Ajanta Pharma

BSE : 532331 | NSE : AJANTPHARM
Industry : Pharma Formulations | ISIN : INE031B01049 | FreeFloat : 29.30% | FnO : No | LotSize : N/A
Intellectual Capital (IC)7,193.74
Net Worth (NW)3,387.99
Intrinsic Worth (IW)10,581.73
Market Cap (MC)15,487.77
Economic Value Added34.66
Discount Rate%
Liquidity Premium%
Knowledge Basis (IC/IW)67.98%
IC Gross Margin (EBITDA/IC)12.03%
IC Net Margin (NPT/IC)8.42%
Knowledge Turnover (Sales/IC)0.55
Market to Intrinsic Value (MC/IW)1.46
As OfIntrinsic ValueMarket Price
31 Mar 2023Rs. 825.89Rs. 1,208.80
7 Jun 2023 ---- Rs. 1,449.90
39.00     2.69%
Fundamental - QualityTechnical - Daily Price actionNear-term Outlook
EVA > 0 : YesBullish10 DMA : Rs. 1,337.11BullishVery Bullish
KB > 50% : Yes50 DMA : Rs. 1,282.96
0 < M2IV < 1 : NoVol-Price trend : Rising
Disclaimer: Sentimeter is based on market data caclulations and is NOT an investment advice

Question 3 - Is this stock undervalued?

Question 2 - Does this business have significant knowledge assets?

Question 1 - Is this business generating enough profits to cover its cost of capital?

* EVA is a registered trademark of Stern Stewart and Co.
Quarterly Results (Rs. Cr)
Quarter
Type*
Sales
Income
EBITDA
EBIT
PBT
PAT
NPT
Jun-20
C
668.20
681.32
236.34
208.32
206.69
147.76
148.54
Sep-20
C
715.91
720.76
279.10
250.77
249.24
170.22
166.36
Dec-20
C
748.74
754.22
247.16
218.02
215.47
176.63
176.77
Mar-21
C
756.84
759.37
261.94
231.34
228.78
159.26
156.44
Jun-21
C
747.99
780.62
252.84
221.96
220.45
173.75
171.75
Sep-21
C
884.80
914.34
292.36
260.82
260.42
195.94
195.29
Dec-21
C
837.91
861.94
263.61
231.89
230.94
191.78
190.19
Mar-22
C
870.29
899.77
236.17
205.01
197.67
151.21
150.41
Jun-22
C
950.93
983.69
254.52
222.74
221.86
174.62
179.82
Sep-22
C
938.10
978.45
236.69
203.99
203.00
156.60
159.26
Dec-22
C
971.77
1006.70
204.48
171.18
168.34
134.51
147.18
Mar-23
C
881.84
918.67
186.20
153.18
152.05
122.25
118.84
* C - Consolidated, S - Standalone

Standard Disclaimer

  1. Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
  2. Past performance, by way of backtesting or by way of actuals, is no guarantee of future returms.
  3. Data mentioned on this page is for educational purpose only and does not constitute investment advice.
Standard Warning - Investment in securities markets are subject to market risk. Read all the related documents carefully before investing.